Catalonia.health collaborates with EY in the fourth session of the Next Health conference series, focused on how the Health & Life Sciences sector is generating tangible impact in sustainability.

Sustainability has evolved from being a moral imperative and a reputation factor to becoming a regulatory obligation. This session evaluates how sustainability generates tangible results for companies and their environment.

A round table discussion will bring together leaders from leading companies in the sector to analyse the progress, challenges, and concrete examples of the impact they are generating in sustainability.

Programme

9:15 AM - Arrival and registration

9:30 AM - Welcome by Hugo Dosil, Partner responsible for the Life Sciences sector at EY Business Consulting, and Eulàlia Griera, Operations Liveable Planet Lead at Ferrer i member at the Shared Valued Committee at Catalonia.health

9:35 AM - Introduction by Antonio Capella, Partner responsible for the Sustainability area at EY in Catalonia

9:45 AM - Roundtable: "How is the H&LS sector generating tangible impact in terms of sustainability?"

• Moderated by Antonio Capella, Partner in charge of Sustainability at EY in Catalonia.
• Speakers:
  • Carlota Gómez de la Hoz, Chief Corporate Affairs and Sustainability Officer at Hipra
  • César Hernández, Global Sustainability Executive Director at Almirall
  • Maria Àngels Valls, Chief Communications and PA Officer at Esteve
  • Isabel Amat, Director of Innovation and Sustainability at Reig Jofre

10:30 AM - Q&A and conclusions

10:50 AM - Networking breakfast

Upcoming sessions in the EY NextHealth innovation conference series:

• 18 March - AI in the Pharmaceutical Industry: transforming the future of healthcare through artificial intelligence

Previous sessions in the EY NextHealth innovation conference series:

• 28 October - Cybersecurity in the pharmaceutical industry
• 26 November - Medicines en route: addressing the challenge and efficiency of pharmaceutical distribution
• 28 January - The future regulation of medicines and medical devices: challenges and opportunities